Treeline Biosciences

Shenandoah Therapeutics has appointed biotechnology veteran Steve Worland as chief executive officer, with co-founder Isabella Graef moving into the chief scientific officer role. The leadership change comes as the company's BCL6-targeting oncology program approaches IND-enabling studies, creating an important test of its transcriptional and epigenetic drug discovery platform.